Generex Biotechnology Announces Postponement of It
Post# of 36537
(Total Views: 433)
Posted On: 05/15/2019 9:09:49 AM
Generex Biotechnology Announces Postponement of Its May 15th Investor Conference Call
9:00 AM ET, 05/15/2019 - GlobeNewswire
MIRAMAR, Fla., May 15, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has postponed the investor conference call scheduled for May 15, 2019. Joseph Moscato, President & Chief Executive Officer of Generex expressed the need to reschedule the call as the company finalizes two current deals. “We feel it is best to finalize these initiatives so that we can present our plan to our investors and shareholders in its entirety,” stated Joseph Moscato. “We have made a point to conduct investor conference call every month to two, so I am disappointed by this postponement. However, I am also confident that once we finalize our current deals, we will be in a better position to discuss all our initiatives in greater detail. We will be announcing a new date for our conference call in the next week. In the meantime, if anyone would like to call me personally, I am always available to my shareholders.”
About Generex Biotechnology Corp.Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immuno-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.
Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.
9:00 AM ET, 05/15/2019 - GlobeNewswire
MIRAMAR, Fla., May 15, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has postponed the investor conference call scheduled for May 15, 2019. Joseph Moscato, President & Chief Executive Officer of Generex expressed the need to reschedule the call as the company finalizes two current deals. “We feel it is best to finalize these initiatives so that we can present our plan to our investors and shareholders in its entirety,” stated Joseph Moscato. “We have made a point to conduct investor conference call every month to two, so I am disappointed by this postponement. However, I am also confident that once we finalize our current deals, we will be in a better position to discuss all our initiatives in greater detail. We will be announcing a new date for our conference call in the next week. In the meantime, if anyone would like to call me personally, I am always available to my shareholders.”
About Generex Biotechnology Corp.Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immuno-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.
Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼